Effect of intravenous iron on endogenous erythropoietin and FGF-23 secretion in patients with chronic kidney disease
Introduction It has been observed that intravenous iron administration may suppress endogenous production of erythropoietin (EPO). We postulate that this effect may be mediated by increased FGF-23 secretion.Aim of the study To evaluate the short-term effect of intravenous iron sucrose administration...
Saved in:
| Main Authors: | Katarzyna Muras-Szwedziak, Ewa Pawłowicz-Szlarska, Michał Nowicki |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2022.2164305 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Recombinant erythropoietin in the treatment of anemia in cancer patients
by: S. V. Vorobiova, et al.
Published: (2022-11-01) -
EFFECT OF ERYTHROPOIETIN ON THE CLINICAL COURSE OF CHRONIC HEART FAILURE IN PATIENTS WITH ANEMIA: RESULTS OF NOT COMPARATIVE STUDY
by: V. M. Provotorov, et al.
Published: (2016-01-01) -
Comparative efficacy Shengxuening and polysaccharide iron complex treatment of anemia in patients with peritoneal dialysis
by: SHI Shao-hua, et al.
Published: (2015-01-01) -
Immunosuppression of spleen in mice treated with erythropoietin: transcriptomic and immunological analysis
by: Xinyi Lyu, et al.
Published: (2025-03-01) -
Protective effect of erythropoietin preconditioning on kidney ischemia-reperfusion injury
by: ZHANG Jiong, et al.
Published: (2017-01-01)